Medical Device News Magazine

Hydrus Microstent

1st Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma

The FRONTIER trial will build on long-term findings from the Hydrus HORIZON five-year pivotal trial, which showed a 47% reduction in visual field loss, sustained reduction in medication use, and over 60% reduction in subsequent, more invasive glaucoma surgery.
- Advertisement -spot_img

Latest News

Oblemic: A Comprehensive Review & Latest Research

Oblemic Reviews suggest that by integrating this supplement with healthy lifestyle choices, individuals may see significant improvements in their health. Unlike injectable treatments such as Ozempic and Wegovy, Oblemic is designed to provide similar benefits without the associated side effects.
- Advertisement -spot_img